Skip to content
Screener

Syndax Pharmaceuticals SNDX Current Debt

Current Debt at other companies

Incyte logo
IncyteINCY
$4.26M-4.8%
Kura Oncology logo
Kura OncologyKURA
$0-100%
AbbVie logo
AbbVieABBV
$0-100%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$1.03B+3,224%
Eli Lilly logo
Eli LillyLLY
$7.05B+23.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$720M—

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K—
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.76B+58.9%
Enterprise value$1.98B+48.9%
P/S8.1×-6.1×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-197154
Current portion of royalty interest financing liabilityMarch 31, 2026 / —December 31, 2025 / —
Royalty interest financing liability, less current portion350,000350,000
Debt issuance costs(6,035)(6,091)
Total royalty interest financing liability, net$343,965$343,909

Item 1: Financial Statements

FAQ

What is Syndax Pharmaceuticals's current debt?
Syndax Pharmaceuticals (SNDX) reported current debt of $350M in Q1 2026.
How has Syndax Pharmaceuticals's current debt changed year-over-year?
Syndax Pharmaceuticals's current debt increased by 4.2% year-over-year, from $335.85M to $350M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Ask your AI about Syndax Pharmaceuticals's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude